Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 2
1996 4
1997 2
1998 1
1999 3
2001 5
2002 4
2003 7
2004 5
2005 6
2006 8
2007 6
2008 8
2009 8
2010 14
2011 5
2012 8
2013 7
2014 8
2015 6
2016 7
2017 6
2018 7
2019 8
2020 8
2021 5
2022 6
2023 3
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 3 Larynx Mucositis or Stomatitis by Clinical Examination Classification, CTCAE"
Page 1
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, Harrington K, Chang PM, Lin JC, Razaq MA, Teixeira MM, Lövey J, Chamois J, Rueda A, Hu C, Dunn LA, Dvorkin MV, De Beukelaer S, Pavlov D, Thurm H, Cohen E. Lee NY, et al. Lancet Oncol. 2021 Apr;22(4):450-462. doi: 10.1016/S1470-2045(20)30737-3. Lancet Oncol. 2021. PMID: 33794205 Clinical Trial.
We aimed to assess if addition of avelumab (anti-PD-L1) to chemoradiotherapy could improve treatment outcomes for this patient population. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 study, patients were recruited from 196 hospitals and ca …
We aimed to assess if addition of avelumab (anti-PD-L1) to chemoradiotherapy could improve treatment outcomes for this patient population. M …
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J. Forastiere AA, et al. N Engl J Med. 2003 Nov 27;349(22):2091-8. doi: 10.1056/NEJMoa031317. N Engl J Med. 2003. PMID: 14645636 Free article. Clinical Trial.
The primary end point was preservation of the larynx. RESULTS: A total of 547 patients were randomly assigned to one of the three study groups. ...The mucosal toxicity of concurrent radiotherapy and cisplatin was nearly twice as frequent as the mucosal …
The primary end point was preservation of the larynx. RESULTS: A total of 547 patients were randomly assigned to one of the th …
Outcome of regenerative therapy for age-related vocal fold atrophy with basic fibroblast growth factor.
Ohno S, Hirano S, Yasumoto A, Ikeda H, Takebayashi S, Miura M. Ohno S, et al. Laryngoscope. 2016 Aug;126(8):1844-8. doi: 10.1002/lary.25578. Epub 2016 Apr 14. Laryngoscope. 2016. PMID: 27075110
Vocal outcomes and stroboscopic examinations were evaluated 1, 3, and 6 months after the injection. The outcome measures included the Voice Handicap Index-10 (VHI-10), GRBAS (grade, roughness, breathiness, asthenia, strain) scale, maximum phonation time (MPT), the a …
Vocal outcomes and stroboscopic examinations were evaluated 1, 3, and 6 months after the injection. The outcome measures included the …
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.
Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, Prevost JB, Modesto A, Lafond C, Tourani JM, Miroir J, Kaminsky MC, Coutte A, Liem X, Chautard E, Vauleon E, Drouet F, Ruffier A, Ramee JF, Waksi G, Péchery A, Wanneveich M, Guigay J, Aupérin A, Bourhis J. Tao Y, et al. Ann Oncol. 2023 Jan;34(1):101-110. doi: 10.1016/j.annonc.2022.10.006. Epub 2022 Oct 28. Ann Oncol. 2023. PMID: 36522816 Free article. Clinical Trial.
RESULTS: Between May 2016 and October 2017, 133 patients were randomized to cetuximab-RT (n = 66) and pembrolizumab-RT (n = 67). Two patients (one in each arm) were not included in the analysis (a consent withdrawal and a progression before treatment start). ...Toxicity wa …
RESULTS: Between May 2016 and October 2017, 133 patients were randomized to cetuximab-RT (n = 66) and pembrolizumab-RT (n = 67). Two …
Evaluation of the Efficacy and Safety of A Novel 0.05% Cyclosporin A Topical Nanoemulsion in Primary Sjögren's Syndrome Dry Eye.
Kang MJ, Kim YH, Chou M, Hwang J, Cheon EJ, Lee HJ, Chung SH. Kang MJ, et al. Ocul Immunol Inflamm. 2020 Apr 2;28(3):370-378. doi: 10.1080/09273948.2019.1587470. Epub 2019 Apr 15. Ocul Immunol Inflamm. 2020. PMID: 30986119 Clinical Trial.
Purpose: To evaluate the efficacy and safety of a novel topical cyclosporin A 0.05% nanoemulsion in comparison with a conventional emulsion in primary Sjogren's syndrome dry eyes.Methods: Prospective, randomized, double-blinded study was conducted.Results: Corneal and conj …
Purpose: To evaluate the efficacy and safety of a novel topical cyclosporin A 0.05% nanoemulsion in comparison with a conventional emulsion …
Targeted laryngeal photodynamic therapy with a balloon diffusing light source.
Grossman C, Zhu T, Finlay J, Dimofte A, Malloy K, O'Malley B Jr, Weinstein G, Busch TM, Quon H. Grossman C, et al. Photodiagnosis Photodyn Ther. 2010 Sep;7(3):158-61. doi: 10.1016/j.pdpdt.2010.06.001. Epub 2010 Aug 3. Photodiagnosis Photodyn Ther. 2010. PMID: 20728839 Free PMC article.
Photodynamic therapy (PDT) has been used for pre-malignant mucosal lesions. In an attempt to treat a patient with recurrent high-grade dysplasia of the glottic larynx, we were faced with technical challenges leading us to abandon the classic microlens fiber f …
Photodynamic therapy (PDT) has been used for pre-malignant mucosal lesions. In an attempt to treat a patient with recurrent high-g …
HYPORT: Phase 1 Study of 3-Week Hypofractionated Postoperative Radiation Therapy for Head and Neck Squamous Cell Carcinoma.
Moon DH, Avkshtol V, Vo D, Ahn C, Sumer B, Day AT, Tillman B, Myers L, Truelson J, Sher DJ. Moon DH, et al. Int J Radiat Oncol Biol Phys. 2024 Jan 1;118(1):157-164. doi: 10.1016/j.ijrobp.2023.06.010. Epub 2023 Jun 26. Int J Radiat Oncol Biol Phys. 2024. PMID: 37380084 Clinical Trial.
No patient experienced a dose-limiting toxicity or grade 4 to 5 toxicity. Acute grade 3 toxicity occurred in 2 patients on level 0 (weight loss, neck abscess) and 3 patients on level 1 (all oral mucositis). ...The follow-up phase 2 randomized …
No patient experienced a dose-limiting toxicity or grade 4 to 5 toxicity. Acute grade 3 toxicity occurred in 2 patients …
Treatment of head and neck cancers: issues for clinical pharmacists.
Scarpace SL, Brodzik FA, Mehdi S, Belgam R. Scarpace SL, et al. Pharmacotherapy. 2009 May;29(5):578-92. doi: 10.1592/phco.29.5.578. Pharmacotherapy. 2009. PMID: 19397465 Review.
Head and neck cancers are a heterogeneous group of diseases involving the oral cavity, pharyngeal tube, and larynx. Given the drug therapy options available, clinical pharmacists can play an important role in the care of this patient population. ...Patients may achi …
Head and neck cancers are a heterogeneous group of diseases involving the oral cavity, pharyngeal tube, and larynx. Given the drug th …
A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Enokida T, Ogawa T, Homma A, Okami K, Minami S, Nakanome A, Shimizu Y, Maki D, Ueda Y, Fujisawa T, Motegi A, Ohkoshi A, Taguchi J, Ebisumoto K, Nomura S, Okano S, Tahara M. Enokida T, et al. Cancer Med. 2020 Mar;9(5):1671-1682. doi: 10.1002/cam4.2852. Epub 2020 Jan 13. Cancer Med. 2020. PMID: 31943834 Free PMC article. Clinical Trial.
Three year overall survival was 83.5%. Main grade 3 toxicities included neutropenia (11.4%) and skin rash (5.7%) during IC; and oral mucositis (31.3%) and neutropenia (12.5%) during CRT. No grade 4 toxicity or treatment-related death was seen. C …
Three year overall survival was 83.5%. Main grade 3 toxicities included neutropenia (11.4%) and skin rash (5.7%) during IC; an …
Comparative Treatment Outcome in T3N0 Glottic Cancer With and Without Vocal Fold Fixation Receiving Radiation Therapy and Concurrent Low-Dose Intra-Arterial Cisplatin Infusion.
Ono T, Tanaka N, Chitose SI, Tanoue S, Kurita T, Sueyoshi S, Fukahori M, Miyata Y, Muraki K, Tsuji C, Ogo E, Hattori C, Sato K, Abe T, Umeno H. Ono T, et al. Ann Otol Rhinol Laryngol. 2022 Aug;131(8):897-904. doi: 10.1177/00034894211047789. Epub 2021 Sep 25. Ann Otol Rhinol Laryngol. 2022. PMID: 34565187
Additionally, the 3-year freedom from laryngectomy, laryngectomy-free survival, and laryngo-esophageal dysfunction-free survival rates of patients with or without VFF were 94.4% and 86.7%, 88.9% and 73.3%, and 83.3% and 73.3%, respectively. Grade …
Additionally, the 3-year freedom from laryngectomy, laryngectomy-free survival, and laryngo-esophageal dysfunction-free survival rate …
144 results